SGLT2 Inhibitors and Euglycemic Ketoacidosis

American Journal of Therapeutics

Volumn 25, Issue 4, 2018, Pages E498-E500

  Masuta, Pardeep ^a   Johri, Geetanjali ^a   Paul, Manju ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; CANAGLIFLOZIN; GLUCOSE; INSULIN GLARGINE; KETONE; LACTIC ACID; METFORMIN; INSULIN;

ABDOMINAL PAIN; ACIDEMIA; ADULT; ANION GAP; BLOOD EXAMINATION; CASE REPORT; CLINICAL ARTICLE; DEHYDRATION; DIABETIC COMPLICATION; DRUG WITHDRAWAL; EUGLYCEMIC KETOACIDOSIS; FEMALE; FLUID RESUSCITATION; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INSULIN INFUSION; KETOACIDOSIS; LETTER; LEUKOCYTOSIS; MIDDLE AGED; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; VOMITING; ANALYSIS; BLOOD; CHEMICALLY INDUCED; DIABETIC KETOACIDOSIS; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; FEMALE; GLUCOSE; HUMANS; INSULIN; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85019595429     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000587     Document Type: Letter

References (4)

1. Novikov A, Vallon V. Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update. Curr Opin Nephrol Hypertens. 2015;25:50-58.
2. Peters A, Buschur E, Buse J, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1687-1693.
3. Taylor S, Blau J, Rother K. SGLT2 inhibitors may predispose to Ketoacidosis. J Clin Endocrinol Metab. 2015; 100:2849-2852.
4. Whalen K, Miller S, Onge E. The role of sodium-glucose Co-Transporter 2 inhibitors in the treatment of type 2 diabetes. Clin Ther. 2015;37:1150-1166.